PARP inhibitors and their evolving role for the treatment of prostate cancer
PARP inhibitors and their evolving role for the treatment of prostate cancer
Disparities in access to oncology clinical trials across Europe
ASCENT: Sacituzumab govitecan vs treatment of physician’s choice in patients with previously treated mTNBC
ALTA-1L: Brigatinib vs crizotinib for ALK advanced non small cell lung cancer patients
Breast cancer roundup from ESMO 2020
OncoAlert and ecancer weekly roundup for September 14-19, 2020
IMpassion130: Atezolizumab and nab-paclitaxel in triple-negative breast cancer
Osimertinib adjuvant therapy in patients with early stage EGFR mutated NSCLC after tumour resection
Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004
CheckMate 649: Nivolumab plus chemotherapy for gastric and oesophageal cancers
AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC
Amivantamab lazertinib and other novel combinations in EGFR positive advanced NSCLC